Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka prefecture, Japan.
Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Ann Surg Oncol. 2017 Nov;24(12):3763-3770. doi: 10.1245/s10434-017-5796-4. Epub 2017 Feb 3.
Recently, several immune checkpoint inhibitors have been developed and are being used to treat malignant melanoma, lung cancer, and other cancers. Several reports have indicated that tumor-infiltrating lymphocytes (TILs) are associated with clinical and histopathologic risk factors in various cancers. However, the role of TILs in esophageal squamous cell carcinoma (ESCC) has not been well studied. This study aimed to investigate the perilesional status of TILs in ESCC and to show associations between TILs and clinical variables.
The study enrolled 277 ESCC patients. Evaluation of TILs was performed according to the criteria of the International TILs Working Group 2014, and associations between TIL and clinicopathologic variables were examined.
Most of the clinicopathologic factors were not statistically associated with TIL status. The number of patients who received adjuvant therapy was significantly larger in the TIL-negative group. Cancer-specific survival (CSS) of patients in the TIL-positive group was significantly better than in the TIL-negative group. Among the patients who received adjuvant therapy, CSS was significantly better in the TIL-positive group than in the TIL-negative group. Uni- and multivariate analyses identified tumor depth and TIL status as independent prognostic factors for CSS. Among the other clinicopathologic variables, TIL status was the strongest CSS indicator.
Tumor-infiltrating lymphocyte status is a strong predictor of good prognosis for ESCC patients.
最近，已经开发出了几种免疫检查点抑制剂，并被用于治疗恶性黑色素瘤、肺癌和其他癌症。有几项报告表明，肿瘤浸润淋巴细胞（TILs）与各种癌症的临床和组织病理学危险因素有关。然而，TILs 在食管鳞状细胞癌（ESCC）中的作用尚未得到很好的研究。本研究旨在探讨 ESCC 肿瘤周围 TIL 的状态，并显示 TIL 与临床变量之间的关联。
该研究纳入了 277 名 ESCC 患者。根据 2014 年国际 TILs 工作组的标准对 TILs 进行评估，并检查 TIL 与临床病理变量之间的关联。
大多数临床病理因素与 TIL 状态无统计学关联。在 TIL 阴性组中，接受辅助治疗的患者数量明显更多。TIL 阳性组的患者癌症特异性生存率（CSS）明显优于 TIL 阴性组。在接受辅助治疗的患者中，TIL 阳性组的 CSS 明显优于 TIL 阴性组。单因素和多因素分析确定肿瘤深度和 TIL 状态是 CSS 的独立预后因素。在其他临床病理变量中，TIL 状态是 CSS 的最强指标。
TIL 状态是 ESCC 患者预后良好的强有力预测指标。
